New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases

WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.

New Global Initiative to Advance Onchocerciasis Vaccine Development for Africa

WASHINGTON, D.C. – August 11, 2015 – The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) has joined The Onchocerciasis Vaccine for Africa (TOVA) Initiative, which was established this year to develop and test a vaccine for onchocerciasis. Also known as river blindness, onchocerciasis infects an estimated 17 million people, with more than 99 percent of these cases spread throughout 31 countries in sub-Saharan Africa. Approximately 169 million people are at risk of contracting this disease.

Dengue Vaccine Initiative Statement on Results of Studies on the Efficacy and Long-Term Safety of Sanofi Pasteur’s Dengue Vaccine Candidate in Dengue-Endemic Regions

WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.